Transforming growth factor-β-induced transcription of the Alzheimer β-amyloid precursor protein gene involves interaction between the CTCF-complex and Smads☆
Section snippets
Materials and methods
Reagents. NHAs and astrocyte growth media were purchased from Clonetics (San Diego). Natural human TGF-β, the Nuclear Protein Extraction Kit (N-xtract) and all other reagents were purchased from Sigma unless otherwise stated. Rabbit polyclonal anti-CTCF type 1 IgG antibody was purchased from Upstate Biotechnology. (Lake Placid, NY), and anti-APP mouse monoclonal (clone 27) antibody to detect APP in AD brain sections was purchased from Zymed. Sheep anti-mouse Ig Texas red-linked whole antibody
Localization of the TGF-β response element to −94/−77 bp of the APP promoter
In the accompanying paper we showed that the proximal, −488 bp fragment of the APP promoter was able to mediate TGF-β effect on APP gene transcription. This proximal promoter region (−488 bp) contains previously characterized nuclear factor binding sites (Fig. 1) that contribute to the promoter activity [5]. To define precisely the TGF-β response element within this domain, deletion constructs of the APP promoter reporter CAT plasmid (−488, −94, −77) and the longest full-length construct −2832
Discussion
Several studies in transgenic mice underscore the potential relevant interactions between TGF-β and APP in the development or progression of AD. In all forms of AD, the abnormal accumulation of Aβ in the brain appears crucial to neurodegeneration. Increased Aβ production and deposition may be largely determined both by synthesis and the subsequent post-translational proteolytic processing of APP. Thus, it is important to study the factors and underlying mechanisms that affect APP synthesis. One
Acknowledgements
We thank Dr. Wolfgang, W. Quitschke, and Dmitry Goldgaber for providing the APP plasmids; Robert Fandrich and Bradley Doble for their excellent technical assistance. We gratefully acknowledge the National Neurological Research Specimen Bank for providing brain tissues. This work was supported by grants from the Scottish Rite Charitable Foundation of Canada and the St. Boniface Hospital Research Foundation.
References (53)
- et al.
Neuron
(1988) J. Biol. Chem
(1994)- et al.
J. Biol. Chem.
(1997) - et al.
Mol. Brain Res.
(1993) - et al.
Brain Res. Brain Res. Rev.
(1997) - et al.
FEBS Lett.
(1994) - et al.
J. Biol. Chem.
(1995) - et al.
J. Neuroimmunol.
(1989) - et al.
Prog. Neurobiol.
(1998) - et al.
Curr. Opin. Cell. Biol.
(1998)
Trends Biochem. Sci.
Cell
Cell
J. Biol. Chem.
J. Biol. Chem.
Immunol. Today
Biochem. Biophys. Res. Commun.
J. Biol. Chem.
J. Biol. Chem.
FEBS Lett.
Proc. Natl. Acad. Sci. USA
Science
Science
Nucl. Acids Res.
NeuroReport
J. Neuropathol. Exp. Neurol.
Cited by (0)
- ☆
Abbreviations: AD, Alzheimer's disease; APP, amyloid precursor protein; Aβ, amyloid β-peptide; NHA, normal human astrocytes; TGF-β1, transforming growth factor-β; CTCF, CTC rich sequence zinc finger domain transcription factor; Smad, vertebrate homologous of Sma and Mad genes; CAT, chloramphenicol acetyltransferase; β-Gal, β-galactosidase.